Palavras-chave
Odontologia preventiva
Drogas antirreabsortivas
Metástase neoplásica
Como Citar
Copyright © | Todos os direitos reservados.
A revista detém os direitos autorais exclusivos de publicação deste artigo nos termos da lei 9610/98.
Reprodução parcial
É livre o uso de partes do texto, figuras e questionário do artigo, sendo obrigatória a citação dos autores e revista.
Reprodução total
É expressamente proibida, devendo ser autorizada pela revista.
Resumo
Objetivo: Analisar a regularidade de encaminhamento médico dos pacientes oncológicos em tratamento com drogas antirreabsortivas para acompanhamento odontológico prévio e contínuo, visando a prevenção da osteonecrose dos maxilares,e se esses pacientes foram devidamente orientados quanto aos efeitos colaterais e fatores de risco associados à terapia medicamentosa. Métodos: Estudo transversal, quantitativo, realizado no hospital de referência em tratamento de câncer, com uma amostra de 70 pacientes em uso de ácido zoledrônico (Zometa®). Os dados foram obtidos por meio de uma entrevista contendo um questionário estruturado com perguntas de múltipla escolha. A inserção dos dados foi feita na plataforma Google Forms, com o objetivo de obter os valores percentuais. Resultados: A maioria dos participantes (85,5%) não foi encaminhada para consulta odontológica antes de iniciar o tratamento com a medicação, 22,8% foram encaminhados durante o tratamento e 72,1% relataram não ter recebido nenhuma informação sobre os efeitos colaterais. Conclusão: O estudo evidencia a necessidade de fortalecer a integração entre as equipes médicas e odontológicas, bem como ampliar as orientações aos pacientes sobre os cuidados preventivos e os possíveis efeitos adversos relacionados às terapias antirreabsortivas.
Referências
ALDHALAAN NA, et al. Medication-related osteonecrosis of the jaw: a review. Cureus, 2020; 12(2): e6944.
AMERICAN ASSOCIATION OF ORAL AND MAXILLOFACIAL SURGEONS (AAOMS). Position paper on bisphosphonate-related osteonecrosis of the jaws. Journal of Oral and Maxillofacial Surgery, 2007; 65(3): 369–376.
BOZYEL B, et al. Hypoxic responses in periodontal tissues: influence of smoking and periodontitis. Journal of Clinical Periodontology, 2025; 52(2): 249–257.
CAMPISI G, et al. Medication-related osteonecrosis of jaws (MRONJ) prevention and diagnosis: Italian consensus update 2020. International Journal of Environmental Research and Public Health, 2020; 17(16): e5922.
CHEN F, et al. Bone marrow niches in the regulation of bone metastasis. Frontiers in Oncology, 2021; 124(12): 1912–1920.
DEAN D, et al. Dental evaluation and clearance prior to allogeneic hematopoietic cell transplantation. Oral Diseases, 2024; 30(4): 2635–2644.
DILLEKAS H, et al. Are 90% of deaths from cancer caused by metastases? Cancer Medicine, 2019; 8(12): 5574–5576.
D'ORONZO S, et al. Metastatic bone disease: pathogenesis and therapeutic options: update on bone metastasis management. Journal of Bone Oncology, 2018; 15: 100232.
HUANG JF, et al. Incidence of patients with bone metastases at diagnosis of solid tumors in adults: a large population-based study. Annals of Translational Medicine, 2020; 8(7): e435.
HONG S, et al. Bone metastasis and skeletal-related events in patients with solid cancer: a Korean Nationwide Health Insurance Database Study. PLoS ONE, 2020; 15(7): e0236025.
JENSEN PR, et al. Bisphosphonates impair the onset of bone formation at remodeling sites. Bone, 2021; 142: 115715.
KIM HW, et al. Comparison of the effect of oral versus intravenous bisphosphonates on RANKL/OPG ratio in jawbones: implications for MRONJ. Journal of Clinical Medicine, 2021; 10(13): e2904.
LEE ES, et al. Bisphosphonates and their connection to dental procedures: exploring bisphosphonate-related osteonecrosis of the jaws. Cancers, 2023; 15(22): e5369.
LORENZO-POUSO AI, et al. Biomarkers to predict the onset of bisphosphonate-related osteonecrosis of the jaw: a systematic review. Medicina Oral, Patología Oral y Cirugía Bucal, 2019; 24(1): 26–36.
MACIEL GBM, et al. O papel da infecção e inflamação na etiopatogênese da osteonecrose dos maxilares induzida por medicamentos. Revista da Faculdade de Odontologia da UPF, 2023; 28(1): e481.
MADEIRA M, et al. Prevention and treatment of oral adverse effects of antiresorptive medications for osteoporosis: a position paper. Archives of Endocrinology and Metabolism, 2020; 64: 664–672.
MARX RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. Journal of Oral and Maxillofacial Surgery, 2003; 61(9): 1115–1117.
MCDONALD D, et al. Treatment of hypercalcaemia of malignancy in adults. Clinical Medicine (Londres), 2023; 23(5): 503–507.
McGOWAN K, et al. Both non-surgical dental treatment and extractions increase the risk of medication-related osteonecrosis of the jaw: case-control study. Clinical Oral Investigations, 2019; 23: 3967–3975.
MOURA AM, et al. Osteorradionecrose em maxila e mandíbula decorrente de tratamento radioterápico. Brazilian Journal of Health Review, 2022; 5(1): 2052–2060.
NOWICKI B, et al. Medication-related osteonecrosis of the jaw in a minipig model: parameters for developing a macroscopic, radiological and microscopic grading scheme. Journal of Craniomaxillofacial Surgery, 2019; 47(7): 1162–1169.
NICOLATOU-GALITIS O, et al. Medication-related osteonecrosis of the jaw: definition and best practice for prevention, diagnosis, and treatment. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2019; 127(2): 117–135.
PAUL J, et al. Smoking and its effects on periodontium – a review. Journal of Pierre Fauchard Academy (India Section), 2022; 36(3): 81–90.
RÁZAVI V, et al. Efficacy of adjunctive photobiomodulation management of medication-related osteonecrosis of the jaw: a systematic review. Photomedicine and Laser Surgery, 2022; 40(12): 777–791.
RUGGIERO SL, et al. Practical guidelines for prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer. Journal of Oncology Practice, 2006; 2(1): 7–14.
RUGGIERO SL, et al. American Association of Oral and Maxillofacial Surgeons’ Position Paper on Medication-Related Osteonecrosis of the Jaws — 2022 Update. Journal of Oral and Maxillofacial Surgery, 2022; 80(5): 920–943.
SAINT-ANDRÉ V, et al. Smoking changes adaptive immunity with persistent effects. Nature, 2024; 615(7951): 125–133.
SEVİNC A. Bisphosphonate osteonecrosis in clinical practice: a scoping review with special emphasis on pamidronate therapy. Clinics in Oncology, 2024; 9(2112): e2112.
SHARMA P, et al. The impact of smoking on periodontal health: a comprehensive review. Journal of Oral Biology and Craniofacial Research, 2024; 14(1): 1–10.
SILVA TSG, et al. Avaliação odontológica prévia ao uso de drogas antirreabsortivas para prevenção da osteonecrose dos maxilares em pacientes com osteoporose. Revista Eletrônica Acervo Saúde, 2024; 24(10): e12048.
SUBRAMANIAN RC, et al. Review of bone modifying agents in metastatic breast cancer. Cureus, 2021; 13(2): e13214.
SURYANI IR, et al. Non-antiresorptive drugs associated with the development of medication-related osteonecrosis of the jaw: a systematic review and meta-analysis. Clinical Oral Investigations, 2022; 26(3): 2269–2279.
TAMMA R, et al. The role of bone stem cell niches in bone metastasis. Applied Sciences, 2020; 10(21): e7534.
TANIOS M, et al. Diabetes and impaired fracture healing: a narrative review of recent literature. Current Osteoporosis Reports, 2022; 20: 229–239.
THOMAS JG, OUANOUNOU A. Medication-related osteonecrosis of the jaw: a narrative review of risk factors, diagnosis, and management. Frontiers of Oral and Maxillofacial Medicine, 2023; 5: 31